BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 63
- Registration Number
- NCT04382586
- Locations
- 🇺🇸
St Jude Medical Center, Fullerton, California, United States
🇺🇸Medstar Heath Research Institute Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸John D Archbold Memorial Hospital, Thomasville, Georgia, United States
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 453
- Registration Number
- NCT04379635
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Capital Medical University Xuanwu Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital - Oncology, Beijing, Beijing, China
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 46
- Registration Number
- NCT04318080
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 97
- Registration Number
- NCT04282018
- Locations
- 🇦🇺
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
🇦🇺Saint Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 537
- Registration Number
- NCT04277637
- Locations
- 🇺🇸
UCLA Hematologyoncology, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Conditions
- Interventions
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 71
- Registration Number
- NCT04276493
- Locations
- 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 342
- Registration Number
- NCT04215978
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence (cCARE), San Diego, California, United States
🇺🇸UPMC Hillman Cancer Center (Univ Of Pittsburgh), Pittsburgh, Pennsylvania, United States
🇦🇺Blacktown Cancer And Haematology Centre, Blacktown, New South Wales, Australia
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT04172246
- Locations
- 🇯🇵
Chiba Cancer Center, Chibashi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohamashi, Kanagawa, Japan
🇯🇵Yokohama Municipal Citizens Hospital, Yokohamashi, Japan
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 500
- Registration Number
- NCT04170283
- Locations
- 🇫🇷
Chu Hopital Lyon Sud, PierreBenite, France
🇮🇹Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi, Pavia, Italy
🇯🇵Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04164199
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China